Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4

Journal of Viral Hepatitis

Volumn 25, Issue 2, 2018, Pages 134-143

  Camus, G ^a   Han, B ^a   Asselah, T ^b   Hsieh, D ^a   Dvory Sobol, H ^a   Lu, J ^a   Svarovskaia, E ^a   Martin, R ^a   Parhy, B ^a   Miller, M D ^a   Brainard, D M ^a   Kersey, K ^a   Abergel, A ^c   Mo, H ^a  

^a GILEAD SCIENCES   (United States)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

direct acting antiviral; hepatitis C virus; ledipasvir; resistance; sofosbuvir; velpatasvir

Indexed keywords

LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; SOFOSBUVIR; VELPATASVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CARBAMIC ACID DERIVATIVE; FLUORENE DERIVATIVE; FUSED HETEROCYCLIC RINGS; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; NS-5 PROTEIN, HEPATITIS C VIRUS; URIDINE PHOSPHATE; VIRAL PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONSENSUS SEQUENCE; DRUG EFFICACY; DRUG POTENCY; EC50; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; REVERTANT; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIRUS ISOLATION; ANALOGS AND DERIVATIVES; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DNA SEQUENCE; DRUG EFFECT; GENETICS; GENOTYPE; HEPACIVIRUS; HIGH THROUGHPUT SEQUENCING; MULTIDRUG RESISTANCE; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARBAMATES; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; SEQUENCE ANALYSIS, DNA; SUSTAINED VIROLOGIC RESPONSE; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85041078373     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12795     Document Type: Article

References (27)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107-15.
2. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-6.
3. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S97-S101.
4. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318-27.
5. Welzel T, Bhardwaj N, Hedskog C, et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol. 2017;67:224-236.
6. Iles JC, Raghwani J, Harrison GL, et al. Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. Virology. 2014;464–465:233-43.
7. Cantaloube JF, Gallian P, Bokilo A, et al. Analysis of hepatitis C virus strains circulating in Republic of the Congo. J Med Virol. 2010;82:562-7.
8. Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL. Genetic diversity of hepatitis C virus in Ethiopia. PLoS ONE. 2017;12:e0179064.
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
10. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350-9.
11. Asselah T, Esmat G, Sanai FM, et al. Simple predictive model for identifying patients with chronic hepatitis C and hepatitis C virus genotype 4 infection with a high probability of sustained virologic response with peginterferon alfa-2a/ribavirin: pooled analysis of data from two large. International Cohort Studies. Adv Ther. 2016;33:1797-813.
12. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2012;56:527-32.
13. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47-57.
14. Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64:1049-1056.
15. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049-54.
16. Asselah T, Bourliere M. Hepatitis C virus: current and evolving treatments for genotype 4. Gastroenterol Clin N Am. 2015;44:859-70.
17. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599-607.
18. Schnell G, Tripathi R, Beyer J, et al. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015;59:6807-15.
19. Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol. 2015;7:2792-810.
20. Hddag HPWG. Clinically relevant HCV drug resistance mutations figure and tables (updated). Ann Forum Collab HIV Res [Internet]. 2012;14:1-10.
21. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110-3.
22. Dong Han KS, Anton ED, Rivera A, et al. Analytical validation of an HCV replicon-based phenotypic assay for evaluating replication capacity and susceptibility of genotype 1a/1b patient viruses to polymerase inhibitors. In: Monogram Biosciences, South San Francisco C, USA, ed. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Los Cabos, Mexico; 2011.
23. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98.
24. ™ (elbasvir and grazoprevir) tablets, for oral use. http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. 2016. Accessed on January 28, 2016.
25. Asante-Appiah E, Curry S, McMonagle P, et al. Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons. Antimicrob Agents Chemother. 2017;61:e00363-17.
26. Halfon P, Mohamed S, Penaranda G, et al. Hepatitis c genotype 4r resistance associated polymorphisms: The achilles heel of the NS5A inhibitors? Hepatology. 2016;64:697-8.
27. Dietz J, Susser S, Peiffer K-H, et al. Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome. EASL. J Hepatol. 2017;66:S525.